A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned
Phase 3
- Conditions
- Acute Coronary Syndrome (Percutaneous Coronary Intervention)
- Registration Number
- JPRN-jRCT2080221435
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Provision of signed informed consent
- Index event of non-ST or ST segment elevation ACS
Exclusion Criteria
- Index event is an acute complication of percutaneous coronary intervention
- Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment
- Oral anticoagulation therapy that cannot be stopped
- The conditions associated with increased risk of bradycardiac events
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method